Michael U. Callaghan

5.1k citations

102 papers · 3.4k · 3 hit papers · h-index 25

Impact in

Hematology top 0.2%
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Hemostasis and retained surgical items
Genetics top 1%
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemoglobinopathies and Related Disorders

Papers in

Hematology 63
- Hemophilia Treatment and Research 36
- Platelet Disorders and Treatments 18
- Iron Metabolism and Disorders 12
- Blood groups and transfusion 11
- Blood Coagulation and Thrombosis Mechanisms 8
Genetics 35
- Hemoglobinopathies and Related Disorders 24
- Myeloproliferative Neoplasms: Diagnosis and Treatment 8

Co-authors: Rebecca Kruse‐Jarres (16 shared papers)Gallia G. Levy (12 shared papers)Johnny Mahlangu (16 shared papers)Johannes Oldenburg (14 shared papers)Midori Shima (14 shared papers)Elina Asikanius (12 shared papers)Christophe Schmitt (7 shared papers)Claude Négrier (4 shared papers)
Journals: Blood (31 papers)Haemophilia (11 papers)Pediatric Blood & Cancer (5 papers)Journal of Clinical Medicine (3 papers)Journal of Pediatric Hematology/Oncology (3 papers)
Partner nations: United States Switzerland Italy

In The Last Decade

Michael U. Callaghan

99 papers receiving 3.3k citations

Michael U. Callaghan's Hit Papers

align trajectories log scale

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors 2018 · 522 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 New England Journal of Medicine
2017 New England Journal of Medicine
2008 Developmental Cell

Peers

Countries citing papers authored by Michael U. Callaghan

Since Specialization

Citations

This map shows the geographic impact of Michael U. Callaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael U. Callaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael U. Callaghan more than expected).

Fields of papers citing papers by Michael U. Callaghan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael U. Callaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael U. Callaghan. The network helps show where Michael U. Callaghan may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael U. Callaghan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael U. Callaghan Line = papers co-authored together Michael U. Callaghan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Emicizumab Prophylaxis in Hemophilia A with Inhibitors New England Journal of Medicine ·Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim, Christophe Schmitt, Michael U. Callaghan, Guy Young, Elena Santagostino, Rebecca Kruse‐Jarres, Claude Négrier, Craig M. Kessler, Nancy Valente, Elina Asikanius, Gallia G. Levy, Jerzy Windyga, Midori Shima Hit paper breakdown →	2017	777
2	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors New England Journal of Medicine ·Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel, Claude Négrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Víctor Jiménez‐Yuste, Christine L. Kempton, Christophe Dhalluin, Michael U. Callaghan, Willem Buján, Midori Shima, Joanne I. Adamkewicz, Elina Asikanius, Gallia G. Levy, Rebecca Kruse‐Jarres Hit paper breakdown →	2018	522
3	UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators Developmental Cell ·D. Thomas Rutkowski, Jun Wu, Sung-Hoon Back, Michael U. Callaghan, Sean P. Ferris, Jahangir Iqbal, Robert L. Clark, Hongzhi Miao, Justin Hassler, Jamie L. Fornek, Michael G. Katze, M. Mahmood Hussain, Benbo Song, Jayanth Swathirajan, Junying Wang, Grace D.-Y. Yau, Randal J. Kaufman Hit paper breakdown →	2008	482
4	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies Blood ·Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse‐Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Víctor Jiménez‐Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg	2020	180
5	Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study Thrombosis and Haemostasis ·Christophe Schmitt, Joanne I. Adamkewicz, Jin Xu, Claire Petry, Olivier Catalani, Guy Young, Claude Négrier, Michael U. Callaghan, Gallia G. Levy	2020	71
6	The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study Haemophilia ·Johannes Oldenburg, Johnny Mahlangu, Willem Buján, Peter C. Trask, Michael U. Callaghan, Guy Young, Elina Asikanius, Flora Peyvandi, Elena Santagostino, Rebecca Kruse‐Jarres, Claude Négrier, Craig M. Kessler, Jin Xu, Jerzy Windyga, Midori Shima, Sylvia von Mackensen	2018	70
7	Electron Spin Resonance of DNA Irradiated with a Heavy-Ion Beam ( 16 O 8+ ): Evidence for Damage to the Deoxyribose Phosphate Backbone Radiation Research ·Dávid Becker, Y.V. Razskazovskii, Michael U. Callaghan, Michael D. Sevilla	1996	67
8	Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection Blood Advances ·Caterina P. Minniti, Ahmar U. Zaidi, Mehdi Nouraie, Deepa Manwani, Gary Crouch, Andrew Crouch, Michael U. Callaghan, Sarah Carpenter, Charleen Jacobs, Jin Han, Jena Simon, Jeffrey Glassberg, Victor R. Gordeuk, Elizabeth S. Klings	2021	52
9	Genotype-phenotype correlation in combined deficiency of factor V and factor VIII Blood ·Bin Zhang, Marta Spreafico, Chunlei Zheng, Angela Yang, Petra Platzer, Michael U. Callaghan, Zekai Avcı, Namık Yaşar Özbek, Johnny Mahlangu, Tabitha Haw, Randal J. Kaufman, Kandice Marchant, Edward G. D. Tuddenham, Uri Seligsohn, Flora Peyvandi, David Ginsburg	2008	50
10	Celastrol induces unfolded protein response-dependent cell death in head and neck cancer Experimental Cell Research ·Andrew M. Fribley, Justin Miller, Amy L. Brownell, Danielle M. Garshott, Qinghua Zeng, Tyler E. Reist, Neha Narula, Peter Y. Cai, Yue Xi, Michael U. Callaghan, Vamsi K. Kodali, Randal J. Kaufman	2014	50
11	Discussing investigational AAV gene therapy with hemophilia patients: A guide Blood Reviews ·Robert F. Sidonio, Steven W. Pipe, Michael U. Callaghan, Leonard A. Valentino, Paul E. Monahan, Stacy E. Croteau	2020	46
12	Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2) Blood ·Rebecca Kruse‐Jarres, Michael U. Callaghan, Stacy E. Croteau, Víctor Jiménez‐Yuste, Liane Khoo, Ri Liesner, Tadashi Matsushita, Michael Recht, Guy Young, Tiffany Chang, Christophe Dhalluin, Yunming Mu, Jin Xu, Jenny Devenport, Richard H. Ko, Paul G. Solari, Johannes Oldenburg	2017	43
13	Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR Oncotarget ·Bo Ren, Hui Liu, Hang Gao, Shutong Liu, Zehui Zhang, Andrew M. Fribley, Michael U. Callaghan, Zhixiang Xu, Qinghua Zeng, Yulin Li	2017	43
14	Novel therapeutics for hemophilia and other bleeding disorders Blood ·Michael U. Callaghan, Robert F. Sidonio, Steven W. Pipe	2018	38
15	Complementary Cell-Based High-Throughput Screens Identify Novel Modulators of the Unfolded Protein Response SLAS DISCOVERY ·Andrew M. Fribley, Patricia G. Cruz, Justin Miller, Michael U. Callaghan, Peter Y. Cai, Neha Narula, Richard R. Neubig, Hollis D. Showalter, Scott D. Larsen, Paul D. Kirchhoff, Martha J. Larsen, Douglas A. Burr, Pamela J. Schultz, Renju R. Jacobs, Giselle Tamayo‐Castillo, David Ron, David H. Sherman, Randal J. Kaufman	2011	37
16	Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma Journal of Clinical Medicine ·Priyanka Shah O’Brien, Yue Xi, Justin Miller, Amy L. Brownell, Qinghua Zeng, George H. Yoo, Danielle M. Garshott, Matthew B. O’Brien, Anthony E. Galinato, Peter Y. Cai, Neha Narula, Michael U. Callaghan, Randal J. Kaufman, Andrew M. Fribley	2019	36
17	The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies Haemophilia ·Mark W. Skinner, Claude Négrier, Ido Paz‐Priel, Sammy Chebon, Víctor Jiménez‐Yuste, Michael U. Callaghan, Michaela Lehle, Markus Niggli, Johnny Mahlangu, Amy D. Shapiro, Midori Shima, Avrita Campinha‐Bacote, Gallia G. Levy, Johannes Oldenburg, Sylvia von Mackensen, Steven W. Pipe	2021	36
18	Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS) Haemophilia ·Johnny Mahlangu, Johannes Oldenburg, Michael U. Callaghan, Midori Shima, Maria Elisa Mancuso, Peter C. Trask, Michael Recht, C. Lorca García, Renchi Yang, Michaela Lehle, Harrison Macharia, Elina Asikanius, Gallia G. Levy, Rebecca Kruse‐Jarres, Sylvia von Mackensen	2019	34
19	The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A Therapeutic Advances in Hematology ·Tristan Knight, Michael U. Callaghan	2018	33
20	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial) Blood Advances ·Ahmed Daak, Carlton Dampier, Beng Fuh, Julie Kanter, Ofelia Álvarez, L. Vandy Black, Melissa A. McNaull, Michael U. Callaghan, Alex George, Lynne Neumayr, Lee Hilliard, F. Sancilio, Adrián L. Rabinowicz, Matthew M. Heeney	2018	32

About Michael U. Callaghan

Michael U. Callaghan is a scholar working on Hematology, Genetics, Molecular Biology, Cell Biology and Physiology, having authored 102 papers that have together received 3.4k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (36 papers), Hemoglobinopathies and Related Disorders (24 papers), Platelet Disorders and Treatments (18 papers), Iron Metabolism and Disorders (12 papers), Blood groups and transfusion (11 papers), Endoplasmic Reticulum Stress and Disease (9 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Blood Coagulation and Thrombosis Mechanisms (8 papers). The work is most often cited by research in Hematology (2.1k citations), Genetics (538 citations), Cell Biology (427 citations), Epidemiology (347 citations) and Molecular Biology (534 citations). Michael U. Callaghan has collaborated with scholars based in United States, Switzerland and Italy. Frequent co-authors include Rebecca Kruse‐Jarres, Gallia G. Levy, Johnny Mahlangu, Johannes Oldenburg, Midori Shima, Elina Asikanius, Christophe Schmitt, Claude Négrier, Guy Young and Elena Santagostino. Their work appears in journals such as Blood, Haemophilia, Pediatric Blood & Cancer, Journal of Clinical Medicine and Journal of Pediatric Hematology/Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Michael U. Callaghan

Impact in

Papers in i

In The Last Decade

Michael U. Callaghan

Michael U. Callaghan's Hit Papers

Peers

Countries citing papers authored by Michael U. Callaghan

Fields of papers citing papers by Michael U. Callaghan

All Works

About Michael U. Callaghan

Explore authors with similar magnitude of impact

Papers in